BRP – Recall of spironolactone

- On January 29, 2021, BRP announced a voluntary, consumer level recall of four lots of spironolactone tablets due to potential mislabeled package displaying incorrect strength information.
- The recalled lots are listed below:

Product Description	NDC#	Lot# (Expiration Date)
Spironolactone 25 mg tablets	63629106401	148969 (7/31/2022)
	63629106402	148791 (7/31/2022)
	63629106403	148991 (7/31/2022)
Spironolactone 50 mg tablets	63629106701	148992 (5/31/2022)

- Spironolactone tablets are indicated for the treatment of heart failure, hypertension, edema associated with hepatic cirrhosis or nephrotic syndrome, and primary hyperaldosteronism.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled spironolactone.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact BRP by phone at **1-877-855-0882** or by email at **cs@brppharma.com** for further information regarding this recall.